Two Dedicated Tracks. One View of Where the Field Is Headed.
As autoimmune cell therapy enters a new phase of clinical maturity, developers are facing a broader set of questions than ever before. How do you measure immune reset? Which modalities are showing the strongest signals? What does commercialization look like? And how can emerging approaches such as in vivo engineering expand patient access?
To help you navigate the meeting, we've highlighted key sessions across both tracks so you can focus on the discussions most relevant to your role, priorities, and stage of development.
Preclinical & Translational Track
Who Are These Sessions Designed For?
- Chief Scientific Officers
- Heads of Discovery
- Heads of Immunology
- Translational Scientists
- Discovery Scientists
- Research Leaders
Explore the Science Defining the Next Generation of Immune Reset
While clinical programs mature, discovery teams are already exploring new targets, biomarkers, engineering platforms, and delivery technologies that could define the future of autoimmune cell therapy.
Key Sessions at This Year’s Meeting:
Speaker:
Speaker:
Speaker:
Speaker:
Speaker:
Speaker:
What is the Value of this Track?
The next wave of autoimmune cell therapy innovation will be determined by discoveries being made today. From novel targets and immune reset biomarkers to in vivo delivery systems and next-generation engineering strategies, this track provides a clear view of where the science is heading next.
Clinical Development Insights
Who Are These Sessions Designed For?
- Chief Medical Officers
- Clinical Development Leaders
- Clinical Scientists
- Translational Medicine Teams
- Medical Affairs
- Physician Scientists
Understand What Clinical Success Looks Like Beyond Proof-of-Concept
Clinical data in autoimmune cell therapy is maturing. This track explores how developers are defining durable responses, optimizing patient selection, evaluating safety, and preparing therapies for broader adoption.
Key Sessions at This Year’s Meeting:
Speaker:
Speaker:
Speaker:
Speaker:
Speaker:
Speaker:
What is the Value of this Track?
The industry's focus is shifting beyond whether autoimmune cell therapies work and toward how they can be delivered safely, consistently, and at scale. This track provides a front-row view into the clinical, operational, and commercialization decisions shaping the next phase of development.
Looking Across Both?
Many of the summit's most important themes, including immune reset, patient selection, biomarkers, manufacturing readiness, commercialization, and in vivo engineering, connect both tracks. We recommend building your schedule around the discussions that align most closely with your immediate strategic priorities.
![CB-CDx-0690-min-scaled11[1]](https://cell-therapy-autoimmune-disease.com/wp-content/uploads/sites/286/2024/06/CB-CDx-0690-min-scaled111.jpg "CB-CDx-0690-min-scaled11[1]")
Explore the Agenda
Discover the latest clinical breakthroughs, translational advances, and commercialization strategies shaping autoimmune cell therapy.
Partner With Us
Connect with the industry's leading autoimmune cell therapy developers as they navigate the next phase of clinical and commercial growth.
Join Cell Therapy Leaders
Attend a highly focused meeting designed specifically for autoimmune disease, enabling more relevant discussions and meaningful connections with peers facing similar challenges.